Immunocore Holdings plc (IMCR) Stock

About Immunocore Holdings plc

Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.

Immunocore Holdings plc is headquartered in GB.

Immunocore Holdings plc (IMCR) stock trades at $31.95 with a market capitalization of $1.62B. The stock is valued at a negative price-to-earnings (P/E) ratio of -85.34, reflecting a net loss over the last twelve months, price-to-book of 4.12, price-to-sales of 4.21. Over the past 52 weeks the stock has ranged between $27.56 and $40.72, and currently trades 21.5% below its 52-week high.

On profitability, Immunocore Holdings plc generates a return on equity (ROE) of -4.83% (negative, reflecting a net loss), return on capital employed of -3.53%, an operating margin of -7.61%, a net profit margin of -4.88%.

Official website: www.immunocore.com

Immunocore Holdings plc by the numbers, 2016–2025

Between 2016 and 2025 Immunocore Holdings plc reported revenue of $16.0M rising to $298.0M, a change of +1762.5% across 10 years. Compounded, revenue has grown 58.3% a year over five years, 27.4% over three, 20.2% over the last twelve months. Net profit fell to $-26.0M.

Operating margin went from -197.3% in 2016 to -11.3% in 2025, a gain of 185.9 percentage points. The most recent net margin is -4.88%. On a trailing twelve-month basis to Mar '26, revenue is $386.0M and net profit $-18.0M.

Borrowings stand at $437.0M, cash on hand is $844.9M, cash from operations was $-8.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged -20.6% over five years, and was -6.8% in the most recent year.

The share price itself has compounded at —% a year over five years, -21.1% over three, -9.9% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Immunocore Holdings plc (IMCR) — frequently asked questions